Tomita, Naohiro
Kunieda, Katsuyuki
Maeda, Atsuyuki
Hamada, Chikuma
Yamanaka, Takeharu
Sato, Toshihiko
Yoshida, Kazuhiro
Boku, Narikazu
Nezu, Riichiro
Yamaguchi, Shigeki
Mishima, Hideyuki
Sadahiro, Sotaro
Muro, Kei
Ishiguro, Megumi
Sakamoto, Junichi
Saji, Shigetoyo
Maehara, Yoshihiko
Article History
Received: 6 August 2018
Revised: 11 January 2019
Accepted: 4 February 2019
First Online: 5 March 2019
Competing interests
: N.T. received research funding from Taiho Pharmaceutical Co. and Chugai Pharmaceutical Co. T.Y. received honoraria from Takeda, Chugai, Taiho, Boehringer Ingelheim. He also received funding from Takeda, Taiho. He has a consulting/advisory role in Gilead Science, Bayer. K.Y. received honoraria from Taiho, Chugai, Takeda, Lilly, Daiichi Sankyo, Ono, Merck Serono, Johnson&Johnson, Covidien, Bayer Yakuhin, Eisai, Olympus, Terumo, Bristol Myers Squibb Japan, Otsuka, Sanofi, Denka, Nippon Kayaku, MSD, and Yakult Honsha. He also received research funding from Sanofi, Yakult Honsha, Chugai, Takeda, Lilly, Ono, Taiho, Daiichi Sankyo, Johnson&Johnson, Covidien, Otsuka, Nippon Kayaku, Tsumura, Asahi Kasei, Eisai, Kyowa Hakko Kirin Astellas, Toyama Chemical, KCI, and Abbot Japan. N.B. received honoraria from Taiho, Chugai, Eli Lilly, Ono, and Bristol Myers Squibb. He also received research funding from Taiho, Ono, and Bristol Myers-Squibb. S.Y. received honoraria and research funding from Chugai and Taiho. H.M. received honoraria and research funding from Chugai. K.M. received honoraria from Chugai, Yakult, Taiho, Takeda, Eli Lilly, and Merck-Serono. He also received research funding from MSD, Daiichi Sankyo, Ono, Shionogi, Kyowa Hakko Kirin, and Gilead Sciences. He has a consulting/advisory role in Ono and Bayer. M.I. received honoraria from Taiho, Chugai, and Merck-Serono and research funding from Taiho and Yakult. He has a consulting/advisory Role in Taiho. J.S. received honoraria from Tsumura and Chugai and has a consulting/advisory role in Takeda. The remaining authors declare no competing interests.
: All data and materials are available by inquiring to Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC).
: Each participating institute’s institutional review board or ethics committee approved the study. The trial followed the principles of the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Conference on Harmonisation. All patients provided written informed consent. Each participating institute’s institutional review board or ethics committee approved the study (see Supplementary Table 1 for a list of institutes).